Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 4,000 shares of the stock in a transaction dated Tuesday, October 17th. The stock was sold at an average price of $71.10, for a total transaction of $284,400.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Lewis Clayton Jr. Cantley also recently made the following trade(s):

  • On Monday, October 16th, Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $71.09, for a total transaction of $71,090.00.
  • On Wednesday, September 13th, Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $65.47, for a total transaction of $65,470.00.
  • On Thursday, September 14th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $65.59, for a total transaction of $262,360.00.
  • On Wednesday, August 23rd, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $56.85, for a total transaction of $227,400.00.
  • On Thursday, July 20th, Lewis Clayton Jr. Cantley sold 9,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $56.36, for a total transaction of $507,240.00.

Shares of Agios Pharmaceuticals, Inc. (AGIO) traded down 1.56% on Wednesday, reaching $69.59. 233,119 shares of the company were exchanged. The company’s market capitalization is $3.37 billion. Agios Pharmaceuticals, Inc. has a 52-week low of $39.24 and a 52-week high of $72.73. The stock has a 50 day moving average of $66.25 and a 200-day moving average of $56.71.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($0.21). Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The business had revenue of $11.30 million during the quarter, compared to analysts’ expectations of $10.68 million. During the same period last year, the company earned ($1.47) EPS. The firm’s revenue for the quarter was up 62.1% on a year-over-year basis. On average, analysts predict that Agios Pharmaceuticals, Inc. will post ($7.08) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Agios Pharmaceuticals, Inc. (AGIO) Director Lewis Clayton Jr. Cantley Sells 4,000 Shares” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/18/agios-pharmaceuticals-inc-agio-director-lewis-clayton-jr-cantley-sells-4000-shares-2.html.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Blue Sky Asset Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the first quarter valued at about $129,000. QS Investors LLC purchased a new stake in shares of Agios Pharmaceuticals in the second quarter valued at about $144,000. Russell Investments Group Ltd. lifted its holdings in shares of Agios Pharmaceuticals by 163.9% in the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 1,583 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in shares of Agios Pharmaceuticals by 1,041.0% in the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 3,123 shares in the last quarter. Finally, Aperio Group LLC purchased a new stake in shares of Agios Pharmaceuticals in the second quarter valued at about $206,000. 93.97% of the stock is currently owned by institutional investors.

Several equities research analysts have recently issued reports on AGIO shares. ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub lowered shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Needham & Company LLC increased their target price on shares of Agios Pharmaceuticals from $54.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, August 10th. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $80.00 price target on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. Finally, Canaccord Genuity set a $90.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 2nd. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $75.20.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.